Tumor microenvironment complexity and therapeutic implications at a glance.

Area of Science:

• Oncology
• Cancer Biology
• Biomedical Engineering

Background:

• Cancer cell interactions with the tumor microenvironment (stromal cells and extracellular matrix) drive tumor heterogeneity, evolution, and metastasis.
• Tumor cells can reprogram stromal cells, altering their function to promote tumor development and invasion.
• These complex interactions are critical for cancer progression and multidrug resistance.

Purpose of the Study:

• To review the potential of understanding cancer cell-microenvironment interactions for developing novel cancer therapies.
• To explore the use of tumor-derived circulating materials as diagnostic tools for predicting and monitoring therapy outcomes.
• To evaluate these potentials in advanced cancer models, including 3D systems and lab-on-chip devices.

Main Methods:

• Literature review of studies on cancer cell-microenvironment interactions.
• Analysis of advanced cancer models such as 3D cultures and lab-on-chip systems.
• Evaluation of diagnostic potential of tumor-derived circulating materials.

Main Results:

• Cancer cell-microenvironment crosstalk significantly influences cancer progression, heterogeneity, and drug resistance.
• Reprogramming of stromal cells by tumor cells is a key mechanism promoting tumor growth and invasion.
• Advanced models like 3D systems and microfluidic devices offer better recapitulation of in vivo tumor biology.
• Tumor-derived circulating materials show promise for non-invasive cancer diagnosis and therapy monitoring.

Conclusions:

• Targeting cancer cell-microenvironment interactions presents a promising avenue for developing innovative cancer treatments.
• Advanced in vitro models are crucial for dissecting these complex interactions and testing therapeutic strategies.
• Circulating tumor materials offer valuable biomarkers for personalized cancer management.
• Further research in these areas can lead to more effective and safer cancer therapies.